BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,774,000 | -3.6% | 11,550,000 | -4.2% | 1.28% | +10.8% |
| Q2 2023 | $84,867,200 | -2.3% | 12,055,000 | +15.7% | 1.15% | -10.6% |
| Q1 2023 | $86,902,800 | -16.4% | 10,420,000 | +15.1% | 1.29% | -17.1% |
| Q4 2022 | $103,894,000 | -8.9% | 9,050,000 | 0.0% | 1.55% | -26.3% |
| Q3 2022 | $114,030,000 | +65.8% | 9,050,000 | +39.2% | 2.11% | +55.0% |
| Q2 2022 | $68,770,000 | +125.6% | 6,500,000 | +246.7% | 1.36% | +144.0% |
| Q1 2022 | $30,488,000 | +1722.4% | 1,875,000 | +450.1% | 0.56% | +415.7% |
| Q4 2017 | $1,673,000 | -82.0% | 340,821 | -80.8% | 0.11% | -85.1% |
| Q3 2017 | $9,319,000 | -14.2% | 1,778,525 | -9.0% | 0.72% | -47.3% |
| Q2 2017 | $10,862,000 | -19.3% | 1,953,525 | +21.9% | 1.37% | -20.2% |
| Q1 2017 | $13,465,000 | +30.4% | 1,603,001 | -1.7% | 1.72% | -17.5% |
| Q4 2016 | $10,327,000 | +69.8% | 1,631,502 | +18.3% | 2.09% | +95.5% |
| Q3 2016 | $6,083,000 | – | 1,379,402 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |